Travatan

RSS

travoprost

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Travatan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Travatan.

This EPAR was last updated on 04/09/2018

Authorisation details

Product details
Name
Travatan
Agency product number
EMEA/H/C/000390
Active substance
travoprost
International non-proprietary name (INN) or common name
travoprost
Therapeutic area (MeSH)
  • Glaucoma, Open-Angle
  • Ocular Hypertension
Anatomical therapeutic chemical (ATC) code
S01EE04
Publication details
Marketing-authorisation holder
Novartis Europharm Limited
Revision
28
Date of issue of marketing authorisation valid throughout the European Union
27/11/2001
Contact address

Elm Park, Merrion Road
Dublin 4
Ireland

Product information

03/08/2018 Travatan - EMEA/H/C/000390 - IA/0060

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).

Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).

Assessment history

How useful was this page?

Add your rating
Average
1 rating